{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:01:46Z","timestamp":1775743306663,"version":"3.50.1"},"reference-count":77,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Allogeneic hematopoietic cell transplantation (HCT) has been used for decades to treat certain malignant and non-malignant hematological conditions, but challenges remain. Increased understanding of disease mechanisms and recent developments in genome editing have enabled alternative strategies utilizing gene-edited autologous HCT and many of these have progressed to the clinic. We present here a comprehensive review of clinical trials of gene-edited autologous hematopoietic stem cells for the treatment of hemoglobinopathies and immunodeficiencies. Searches of major international clinical trial registries were carried out using specific key words. In total, 44 interventional clinical trials investigating gene-edited autologous stem cell therapies were identified, with CASGEVY (exagamglogene autotemcel) being the only product approved to date. Hemoglobinopathies were the most common indication (n = 37) followed by immunodeficiencies (n = 4), with single trials in HIV-1 infection, pyruvate kinase deficiency and limb\u2013girdle muscular dystrophy. Gene-editing strategies fall into three categories: disruption of the BCL11A erythroid enhancer, editing of the \u03b3-globin promoter and direct correction or disruption of disease-relevant genes. CD34+ hematopoietic stem and progenitor cells are the most common cell types edited, and CRISPR-Cas9 is the most widely used gene-editing modality. While results are encouraging, efficient intracellular delivery of gene-editing tools, editing efficiencies and off-target editing remain challenges for the field.<\/jats:p>","DOI":"10.3390\/ijms27083384","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:09:31Z","timestamp":1775740171000},"page":"3384","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Trial Landscape of Gene-Edited Autologous Hematopoietic Stem Cells for Hemoglobinopathies and Immunodeficiencies"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7782-9907","authenticated-orcid":false,"given":"Karen","family":"O\u2019Hanlon Cohrt","sequence":"first","affiliation":[{"name":"CRISPR Medicine ApS, Kong Georgs Vej 12, 2000 Frederiksberg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"O\u2019Dea","sequence":"additional","affiliation":[{"name":"Biology Department, Maynooth University, W23 F2H6 Kildare, Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1007\/s12015-022-10330-2","article-title":"New insights into Human Hematopoietic Stem and Progenitor Cells via Single-Cell Omics","volume":"18","author":"Zhang","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3747\/co.26.5033","article-title":"A general practitioner\u2019s guide to hematopoietic stem-cell transplantation","volume":"26","author":"Bazinet","year":"2019","journal-title":"Curr. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"409.e1","DOI":"10.1016\/j.jtct.2022.04.012","article-title":"Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes","volume":"28","author":"Phelan","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: Current practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1097\/MS9.0000000000002146","article-title":"Revolutionary breakthrough: FDA approves CASGEVY, the first CRISPR\/Cas9 gene therapy for sickle cell disease","volume":"86","author":"Singh","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101135","DOI":"10.1016\/j.omtm.2023.101135","article-title":"Development of a gene edited next-generation hematopoietic cell transplant to enable acute myeloid leukemia treatment by solving off-tumor toxicity","volume":"31","author":"Lydeard","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bcmd.2017.12.001","article-title":"Gene therapy and gene editing strategies for hemoglobinopathies","volume":"70","author":"Lidonnici","year":"2018","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102419","DOI":"10.1016\/j.xcrm.2025.102419","article-title":"Gene therapy for hemoglobinopathies: Clinical trial results and biology of hematopoietic stem cell and the bone marrow niche","volume":"6","author":"Aprile","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"102666","DOI":"10.1016\/j.omtn.2025.102666","article-title":"Advancing gene editing therapeutics: Clinical trials and innovative delivery systems across diverse diseases","volume":"36","author":"Raigani","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e70148","DOI":"10.1096\/fj.202401692R","article-title":"Prime editing: A gene precision editing tool from inception to present","volume":"38","author":"Liu","year":"2024","journal-title":"FASEB J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7208","DOI":"10.1038\/s41467-025-62606-z","article-title":"The hidden risks of CRISPR\/Cas: Structural variations and genome integrity","volume":"16","author":"Aussel","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1186\/s12967-024-05957-3","article-title":"From bench to bedside: Cutting-edge applications of base editing and prime editing in precision medicine","volume":"22","author":"Xu","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/s41587-023-02050-w","article-title":"Glycosylase-based base editors for efficient T-to-G and C-to-G editing in mammalian cells","volume":"42","author":"Ye","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41434-023-00434-w","article-title":"CRISPR\/Cas9-mediated base editors and their prospects for mitochondrial genome engineering","volume":"31","author":"Eghbalsaied","year":"2024","journal-title":"Gene Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"24298","DOI":"10.1038\/s41598-024-74716-7","article-title":"Zinc finger nuclease-mediated gene editing in hematopoietic stem cells results in reactivation of fetal hemoglobin in sickle cell disease","volume":"14","author":"Lessard","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2021-147907","article-title":"Updated Results of a Phase 1\/2 Clinical Study of Zinc Finger Nuclease-Mediated Editing of BCL11A in Autologous Hematopoietic Stem Cells for Transfusion-Dependent Beta Thalassemia","volume":"138","author":"Walters","year":"2021","journal-title":"Blood"},{"key":"ref_17","unstructured":"Zheng, B., Liu, R., Zhang, X., Fu, B., Xu, Y., Shi, J., Feng, X., Li, D., Wu, Y., and Liu, M. (2026, January 18). Efficacy and Safety of BRL-101 in TDT and SCD. EHA Library, Conference Abstract, p. S290. Available online: https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4159367\/tan.qian.efficacy.and.safety.of.brl-101.in.tdt.and.scd.html?f=."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.1182\/blood-2023-186031","article-title":"Efficacy and Safety of Brl-101, CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer in Transfusion-Dependent \u03b2-Thalassemia","volume":"142","author":"Zheng","year":"2023","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 Gene Editing for Sickle Cell Disease and \u03b2-Thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene Autotemcel for Transfusion-Dependent \u03b2-Thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_21","unstructured":"(2026, January 18). Beam Therapeutics Reports Updated Data from BEACON Phase 1\/2 Trial of Ristoglogene Autogetemcel (Risto-Cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting. Available online: https:\/\/www.globenewswire.com\/news-release\/2025\/12\/06\/3201044\/0\/en\/Beam-Therapeutics-Reports-Updated-Data-from-BEACON-Phase-1-2-Trial-of-ristoglogene-autogetemcel-risto-cel-Highlighting-Durable-Differentiated-Profile-in-Sickle-Cell-Disease-SCD-at-.html."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6090","DOI":"10.1182\/blood-2025-6090","article-title":"Rapid, efficient and durable fetal hemoglobin production following CS-101 treatment in transfusion-dependent \u03b2-thalassemia participants: An autologous, ex vivo edited CD34+ stem cell product using the innovative transformer base editor (tBE)","volume":"146","author":"Chen","year":"2025","journal-title":"Blood"},{"key":"ref_23","unstructured":"(2026, January 18). CS-101: Base-Editing Therapy Treats Hemoglobinopathy Patients in World First. Available online: https:\/\/www.regmednet.com\/cs-101-base-editing-therapy-treats-hemoglobinopathy-patients-in-world-first\/."},{"key":"ref_24","unstructured":"(2026, January 18). High-Precision Base Editing Clinical Treatment for Sickle Cell Disease\u2014CorrectSequence Therapeutics\u2019 CS-101 Achieves Promising Results in First Patient. Available online: https:\/\/www.correctsequence.com\/news\/shownews.php?id=472&lang=en."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa2215643","article-title":"CRISPR-Cas9 Editing of the HBG1 and HBG2 Promoters to Treat Sickle Cell Disease","volume":"389","author":"Sharma","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1182\/blood-2024-208623","article-title":"Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Successful Engraftment, Increased Hemoglobin, and Reduced Transfusion Dependence in Patients with Transfusion-Dependent Beta-Thalassemia Treated in the Edithal Trial","volume":"144","author":"Frangoul","year":"2024","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1182\/blood-2024-210343","article-title":"Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial","volume":"144","author":"Hanna","year":"2024","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1182\/blood-2024-206549","article-title":"Updated Safety and Efficacy Results of RM-001, Autologous HBG1\/2 Promoter-Modified CD34+ Hematopoietic Stem and Progenitor Cells, in Treating Transfusion-Dependent \u03b2-Thalassemia","volume":"144","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1182\/blood-2023-188963","article-title":"One Year Follow-up on the First Patient Treated with Nula-Cel: An Autologous CRISPR\/Cas9 Gene Corrected CD34+ Cell Product to Treat Sickle Cell Disease","volume":"142","author":"Shyr","year":"2023","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/blood-2025-382","article-title":"Curing Hemoglobin H-Constant Spring through Base Editing of Autologous CD34+ Hematopoietic Stem and Progenitor Cells","volume":"146","author":"Wang","year":"2025","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa2509807","article-title":"Prime Editing for p47phox-Deficient Chronic Granulomatous Disease","volume":"394","author":"Gori","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/bmb\/ldad017","article-title":"Mobilization-based engraftment of haematopoietic stem cells: A new perspective for chemotherapy-free gene therapy and transplantation","volume":"147","author":"Canarutto","year":"2023","journal-title":"Br. Med. Bull."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1016\/j.ymthe.2023.09.006","article-title":"Prospects and challenges of in vivo hematopoietic stem cell genome editing for hemoglobinopathies","volume":"31","author":"Lieber","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102457","DOI":"10.1016\/j.omtn.2025.102457","article-title":"Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group","volume":"36","author":"Cavazza","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/GIM.0b013e3181cd68ed","article-title":"Beta-thalassemia","volume":"12","author":"Cao","year":"2010","journal-title":"Genet. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMra2021838","article-title":"\u03b2-Thalassemias","volume":"384","author":"Taher","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/gim.2016.173","article-title":"\u03b2-Thalassemia","volume":"19","author":"Origa","year":"2017","journal-title":"Genet. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/bjh.17091","article-title":"Co-morbidities and mortality associated with transfusion-dependent beta-thalassaemia in patients in England: A 10-year retrospective cohort analysis","volume":"191","author":"Jobanputra","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40271-020-00473-0","article-title":"Patient- and Caregiver-Reported Burden of Transfusion-Dependent \u03b2-Thalassemia Measured Using a Digital Application","volume":"14","author":"Paramore","year":"2021","journal-title":"Patient"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11136-018-1986-1","article-title":"Health-related quality of life (HRQoL) in beta-thalassemia major (\u03b2-TM) patients assessed by 36-item short form health survey (SF-36): A meta-analysis","volume":"28","author":"Arian","year":"2019","journal-title":"Qual. Life Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"100588","DOI":"10.1016\/j.blre.2019.100588","article-title":"Challenges of blood transfusions in \u03b2-thalassemia","volume":"37","author":"Shah","year":"2019","journal-title":"Blood Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMct0708272","article-title":"Hydroxyurea for the treatment of sickle cell anemia","volume":"358","author":"Platt","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_44","first-page":"CD002202","article-title":"Hydroxyurea (hydroxycarbamide) for sickle cell disease","volume":"4","author":"Nevitt","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","article-title":"A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent \u03b2-Thalassemia","volume":"382","author":"Cappellini","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/asheducation-2017.1.278","article-title":"New therapeutic targets in transfusion-dependent and -independent thalassemia","volume":"2017","author":"Cappellini","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2174\/156652408786241393","article-title":"Recent advances in bone marrow transplantation in hemoglobinopathies","volume":"8","author":"Michlitsch","year":"2008","journal-title":"Curr. Mol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ymthe.2024.01.015","article-title":"A new frontier: FDA approvals for gene therapy in sickle cell disease","volume":"32","author":"Leonard","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"150930","DOI":"10.1016\/j.tmrv.2025.150930","article-title":"Gene Therapies for Hemoglobinopathies: Efficacy, Cell Collection & Transfusion Support","volume":"39","author":"Inam","year":"2025","journal-title":"Transfus. Med. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/S0140-6736(24)01884-1","article-title":"Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype \u03b2-thalassaemia (HGB-212): A non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial","volume":"404","author":"Kwiatkowski","year":"2024","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Weatherall, D.J., and Clegg, J.B. (2001). The Thalassaemia Syndromes, Blackwell Science. [4th ed.].","DOI":"10.1002\/9780470696705"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V84.2.643.643","article-title":"The Acute Chest Syndrome in Sickle Cell Disease: Incidence and Risk Factors","volume":"84","author":"Castro","year":"1994","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199107043250103","article-title":"Pain in sickle cell disease. Rates and risk factors","volume":"325","author":"Platt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/35066048","article-title":"Phenotype-genotype relationships in monogenic disease: Lessons from the thalassaemias","volume":"2","author":"Weatherall","year":"2001","journal-title":"Nat. Rev. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/S0140-6736(05)67396-5","article-title":"Haemoglobin E \u03b2 thalassaemia in Sri Lanka","volume":"366","author":"Premawardhena","year":"2005","journal-title":"Lancet"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1182\/blood-2009-04-217901","article-title":"Amelioration of Sardinian beta0 thalassemia by genetic modifiers","volume":"114","author":"Galanello","year":"2009","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00439-009-0770-2","article-title":"A genome-wide association identified the common genetic variants influence disease severity in beta0-thalassemia\/hemoglobin E","volume":"127","author":"Nuinoon","year":"2010","journal-title":"Hum. Genet."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"a011643","DOI":"10.1101\/cshperspect.a011643","article-title":"The switch from fetal to adult hemoglobin","volume":"3","author":"Sankaran","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"11869","DOI":"10.1073\/pnas.0804799105","article-title":"DNA polymorphisms at the BCL11A, HBS1L-MYB, and \u03b2-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease","volume":"105","author":"Lettre","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1073\/pnas.0711566105","article-title":"Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia","volume":"105","author":"Uda","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/ng2108","article-title":"A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15","volume":"39","author":"Menzel","year":"2007","journal-title":"Nat. Genet."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11346","DOI":"10.1073\/pnas.0611393104","article-title":"Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults","volume":"104","author":"Thein","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.2010.08105.x","article-title":"Advances in the understanding of haemoglobin switching","volume":"149","author":"Sankaran","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1126\/science.1165409","article-title":"Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A","volume":"322","author":"Sankaran","year":"2008","journal-title":"Science"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2010-08-300723","article-title":"Therapeutic levels of fetal hemoglobin in erythroid progeny of \u03b2-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer","volume":"117","author":"Wilber","year":"2011","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/ng.637","article-title":"KLF1 regulates BCL11A expression and \u03b3- to \u03b2-globin gene switching","volume":"42","author":"Zhou","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/ng.630","article-title":"Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin","volume":"42","author":"Borg","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1056\/NEJMoa1103070","article-title":"A functional element necessary for fetal hemoglobin silencing","volume":"365","author":"Sankaran","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nature15521","article-title":"BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis","volume":"527","author":"Canver","year":"2015","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"eadj6779","DOI":"10.1126\/scitranslmed.adj6779","article-title":"High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease","volume":"16","author":"Bzhilyanskaya","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"ref_74","first-page":"1","article-title":"Sensitive and unbiased genome-wide profiling of base-editor-induced off-target activity using CHANGE-seq-BE","volume":"44","author":"Lazzarotto","year":"2026","journal-title":"Nat. Biotechnol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"16067","DOI":"10.1038\/mtm.2016.67","article-title":"Preclinical development and qualification of ZFN-mediated CCR5 disruption in human hematopoietic stem\/progenitor cells","volume":"3","author":"DiGiusto","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00018-025-05904-5","article-title":"Cell therapy for Duchenne muscular dystrophy: Promises, challenges, and controversies","volume":"82","author":"Dulak","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41434-021-00284-4","article-title":"Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI)","volume":"30","author":"Adair","year":"2023","journal-title":"Gene Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/8\/3384\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:09:56Z","timestamp":1775740196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/8\/3384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":77,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ijms27083384"],"URL":"https:\/\/doi.org\/10.3390\/ijms27083384","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}